Design, synthesis, and biological evaluation of novel 4-phenoxypyridine derivatives as potential antitumor agents. 2019

Ju Liu, and Yutong Liu, and Xuechen Hao, and Yang Wang, and Jingchao Ji, and Yajing Liu, and Shi Ding, and Ye Chen
Key Laboratory of New Drug Research and Development of Liaoning Province, College of Pharmacy Liaoning University, Shenyang, P. R. China.

A series of novel 4-phenoxypyridine derivatives containing the 4-oxo-1,4-dihydropyridazine-3-carboxamide moiety were synthesized and evaluated for their in vitro cytotoxic activity against the A549 cancer cell line, and some compounds were further examined for their cytotoxic activity against the H460, BGC823, MKN45, and HT-29 cancer cell lines. Most of the compounds exhibited moderate to significant cytotoxicity. The most promising compound 15b (with VEGFR2 inhibitory concentration [IC50 ] value of 0.23 μM) showed remarkable cytotoxicity against A549, BGC-823, MKN45, H460, and HT-29 cells, with IC50 values of 0.75, 1.68, 2.63, 5.08 and 7.22 μM, respectively. Their preliminary structure-activity relationship studies indicate that electron-withdrawing groups on the terminal phenyl rings are beneficial for improving the antitumor activity. Moreover, treatment of A549 cells with compound 15b resulted in cell cycle arrest in the G0 /G1 phase in a dose-dependent manner. Further apoptotic studies and acridine orange/ethidium bromide staining were also performed on A549 cells, which showed that compound 15b could induce apoptosis. Wound-healing assay results indicated that compound 15b strongly inhibited A549 cell motility.

UI MeSH Term Description Entries
D011725 Pyridines Compounds with a six membered aromatic ring containing NITROGEN. The saturated version is PIPERIDINES.
D002453 Cell Cycle The complex series of phenomena, occurring between the end of one CELL DIVISION and the end of the next, by which cellular material is duplicated and then divided between two daughter cells. The cell cycle includes INTERPHASE, which includes G0 PHASE; G1 PHASE; S PHASE; and G2 PHASE, and CELL DIVISION PHASE. Cell Division Cycle,Cell Cycles,Cell Division Cycles,Cycle, Cell,Cycle, Cell Division,Cycles, Cell,Cycles, Cell Division,Division Cycle, Cell,Division Cycles, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004354 Drug Screening Assays, Antitumor Methods of investigating the effectiveness of anticancer cytotoxic drugs and biologic inhibitors. These include in vitro cell-kill models and cytostatic dye exclusion tests as well as in vivo measurement of tumor growth parameters in laboratory animals. Anticancer Drug Sensitivity Tests,Antitumor Drug Screens,Cancer Drug Tests,Drug Screening Tests, Tumor-Specific,Dye Exclusion Assays, Antitumor,Anti-Cancer Drug Screens,Antitumor Drug Screening Assays,Tumor-Specific Drug Screening Tests,Anti Cancer Drug Screens,Anti-Cancer Drug Screen,Antitumor Drug Screen,Cancer Drug Test,Drug Screen, Anti-Cancer,Drug Screen, Antitumor,Drug Screening Tests, Tumor Specific,Drug Screens, Anti-Cancer,Drug Screens, Antitumor,Drug Test, Cancer,Drug Tests, Cancer,Screen, Anti-Cancer Drug,Screen, Antitumor Drug,Screens, Anti-Cancer Drug,Screens, Antitumor Drug,Test, Cancer Drug,Tests, Cancer Drug,Tumor Specific Drug Screening Tests
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships
D015195 Drug Design The molecular designing of drugs for specific purposes (such as DNA-binding, enzyme inhibition, anti-cancer efficacy, etc.) based on knowledge of molecular properties such as activity of functional groups, molecular geometry, and electronic structure, and also on information cataloged on analogous molecules. Drug design is generally computer-assisted molecular modeling and does not include PHARMACOKINETICS, dosage analysis, or drug administration analysis. Computer-Aided Drug Design,Computerized Drug Design,Drug Modeling,Pharmaceutical Design,Computer Aided Drug Design,Computer-Aided Drug Designs,Computerized Drug Designs,Design, Pharmaceutical,Drug Design, Computer-Aided,Drug Design, Computerized,Drug Designs,Drug Modelings,Pharmaceutical Designs
D015394 Molecular Structure The location of the atoms, groups or ions relative to one another in a molecule, as well as the number, type and location of covalent bonds. Structure, Molecular,Molecular Structures,Structures, Molecular
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Ju Liu, and Yutong Liu, and Xuechen Hao, and Yang Wang, and Jingchao Ji, and Yajing Liu, and Shi Ding, and Ye Chen
February 2018, Bioorganic & medicinal chemistry letters,
Ju Liu, and Yutong Liu, and Xuechen Hao, and Yang Wang, and Jingchao Ji, and Yajing Liu, and Shi Ding, and Ye Chen
September 2018, Molecules (Basel, Switzerland),
Ju Liu, and Yutong Liu, and Xuechen Hao, and Yang Wang, and Jingchao Ji, and Yajing Liu, and Shi Ding, and Ye Chen
January 2019, Frontiers in chemistry,
Ju Liu, and Yutong Liu, and Xuechen Hao, and Yang Wang, and Jingchao Ji, and Yajing Liu, and Shi Ding, and Ye Chen
February 2021, Molecules (Basel, Switzerland),
Ju Liu, and Yutong Liu, and Xuechen Hao, and Yang Wang, and Jingchao Ji, and Yajing Liu, and Shi Ding, and Ye Chen
February 2021, Bioorganic & medicinal chemistry letters,
Ju Liu, and Yutong Liu, and Xuechen Hao, and Yang Wang, and Jingchao Ji, and Yajing Liu, and Shi Ding, and Ye Chen
November 2021, Drug development research,
Ju Liu, and Yutong Liu, and Xuechen Hao, and Yang Wang, and Jingchao Ji, and Yajing Liu, and Shi Ding, and Ye Chen
November 2013, Bioorganic & medicinal chemistry,
Ju Liu, and Yutong Liu, and Xuechen Hao, and Yang Wang, and Jingchao Ji, and Yajing Liu, and Shi Ding, and Ye Chen
February 2017, Bioorganic & medicinal chemistry letters,
Ju Liu, and Yutong Liu, and Xuechen Hao, and Yang Wang, and Jingchao Ji, and Yajing Liu, and Shi Ding, and Ye Chen
December 2022, Journal of enzyme inhibition and medicinal chemistry,
Ju Liu, and Yutong Liu, and Xuechen Hao, and Yang Wang, and Jingchao Ji, and Yajing Liu, and Shi Ding, and Ye Chen
September 2019, European journal of medicinal chemistry,
Copied contents to your clipboard!